NASDAQ:RARE

Ultragenyx Pharmaceutical Stock Forecast, Price & News

$108.72
-0.86 (-0.78 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$107.66
Now: $108.72
$110.73
50-Day Range
$100.53
MA: $118.69
$142.47
52-Week Range
$54.73
Now: $108.72
$179.65
Volume378,406 shs
Average Volume454,731 shs
Market Capitalization$7.28 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.19
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Ultragenyx Pharmaceutical logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARE
CUSIPN/A
Phone415-483-8800
Employees893
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$103.71 million
Book Value$11.32 per share

Profitability

Net Income$-402,730,000.00
Net Margins-119.19%

Miscellaneous

Market Cap$7.28 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

Headlines

Mereo BioPharma: An Overlooked Bio Company
March 26, 2021 |  seekingalpha.com
RARE Crosses Below Key Moving Average Level
March 26, 2021 |  nasdaq.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 6%
March 25, 2021 |  americanbankingnews.com
RARE May 2021 150.000 call
March 19, 2021 |  in.finance.yahoo.com
Ultragenyx: Multiple Potential Catalysts Ahead
February 19, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.44 out of 5 stars

Medical Sector

600th out of 2,024 stocks

Pharmaceutical Preparations Industry

280th out of 772 stocks

Analyst Opinion: 3.3Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$108.72
-0.86 (-0.78 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

Is Ultragenyx Pharmaceutical a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 6 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ultragenyx Pharmaceutical stock.
View analyst ratings for Ultragenyx Pharmaceutical
or view top-rated stocks.

What stocks does MarketBeat like better than Ultragenyx Pharmaceutical?

Wall Street analysts have given Ultragenyx Pharmaceutical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ultragenyx Pharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Ultragenyx Pharmaceutical
.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its quarterly earnings results on Thursday, February, 11th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.06) by $0.28. The biopharmaceutical company had revenue of $91.54 million for the quarter, compared to analyst estimates of $71.15 million. Ultragenyx Pharmaceutical had a negative trailing twelve-month return on equity of 50.69% and a negative net margin of 119.19%.
View Ultragenyx Pharmaceutical's earnings history
.

How has Ultragenyx Pharmaceutical's stock price been impacted by COVID-19?

Ultragenyx Pharmaceutical's stock was trading at $45.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RARE stock has increased by 139.7% and is now trading at $108.72.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RARE?

14 Wall Street analysts have issued 1-year price objectives for Ultragenyx Pharmaceutical's stock. Their forecasts range from $66.00 to $186.00. On average, they expect Ultragenyx Pharmaceutical's stock price to reach $131.20 in the next year. This suggests a possible upside of 20.7% from the stock's current price.
View analysts' price targets for Ultragenyx Pharmaceutical
or view top-rated stocks among Wall Street analysts.

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the following people:
  • Dr. Emil D. Kakkis M.D., Ph.D., Pres, CEO & Director (Age 61, Pay $1.23M)
  • Mr. Thomas R. Kassberg, Chief Bus. Officer & Exec. VP (Age 61, Pay $714.84k)
  • Mr. John Richard Pinion II, Chief Quality Operations Officer & Exec. VP of Translational Sciences (Age 55, Pay $690.65k)
  • Dr. Camille L. Bedrosian, Chief Medical Officer & Exec. VP (Age 68, Pay $755.15k)
  • Ms. Mardi C. Dier, Exec. VP & CFO (Age 57)
  • Mr. Theodore A. Huizenga, VP, Corp. Controller & Principal Accounting Officer (Age 50)
  • Mr. Dennis Karl Huang, Chief Technical Operations Officer & Exec. VP (Age 56)
  • Ms. Danielle Keatley, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Karah Herdman Parschauer J.D., Gen. Counsel & Exec. VP (Age 43)
  • Mr. Ernie W. Meyer, Chief HR Officer & Exec. VP (Age 57)

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical CEO Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among Ultragenyx Pharmaceutical's employees.

Who are some of Ultragenyx Pharmaceutical's key competitors?

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional investors include Cardan Capital Partners LLC (0.06%), Pacer Advisors Inc. (0.00%) and Valeo Financial Advisors LLC (0.00%). Company insiders that own Ultragenyx Pharmaceutical stock include Camille L Bedrosian, Clay B Siegall, Emil D Kakkis, John Richard Pinion, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
View institutional ownership trends for Ultragenyx Pharmaceutical
.

Which institutional investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Camille L Bedrosian, Clay B Siegall, Emil D Kakkis, John Richard Pinion, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg, and William Aliski.
View insider buying and selling activity for Ultragenyx Pharmaceutical
or view top insider-selling stocks.

Which institutional investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was acquired by a variety of institutional investors in the last quarter, including Cardan Capital Partners LLC, and Valeo Financial Advisors LLC.
View insider buying and selling activity for Ultragenyx Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $108.72.

How much money does Ultragenyx Pharmaceutical make?

Ultragenyx Pharmaceutical has a market capitalization of $7.28 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis.

How many employees does Ultragenyx Pharmaceutical have?

Ultragenyx Pharmaceutical employs 893 workers across the globe.

What is Ultragenyx Pharmaceutical's official website?

The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.

Where are Ultragenyx Pharmaceutical's headquarters?

Ultragenyx Pharmaceutical is headquartered at 60 Leveroni Court, Novato CA, 94949.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.